Prihlásiť sa Zaregistrujte sa zadarmo

% krátkych akcií spoločnosti RepliCel Life Sciences

Aká je hodnota metriky % krátkych akcií spoločnosti RepliCel Life Sciences?

Hodnota metriky % krátkych akcií spoločnosti RepliCel Life Sciences, Inc. je 0.00%

Aká je definícia metriky % krátkych akcií?



% krátkych akcií (Short % of float) je počet akcií predaných na krátko v porovnaní so všetkými akciami v obehu (float) vyjadrený v percentách.

Short percentage of float, or short interest ratio, is calculated by taking the total amount of shares shorted and dividing it by the total amount of shares available for trade. It is an indirect metric of investor sentiment. When short percentage of float is high, above 40%, it implies company investors hope shares will decline in value. The percentage is used by both fundamental and technical traders to identify trends. The short percentage of float can also be calculated for entire exchanges to determine the sentiment of the market as a whole. If it is high of around five or greater for an exchange, this can be taken as a bearish signal, and vice versa.

% krátkych akcií spoločností v sektore Health Care sektor na TSXV v porovnaní so spoločnosťou RepliCel Life Sciences

Čomu sa venuje spoločnosť RepliCel Life Sciences?

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.

Firmy s metrikou % krátkych akcií podobnou spoločnosti RepliCel Life Sciences